PL2542576T3 - Sposoby badań przesiewowych przeciwciał - Google Patents
Sposoby badań przesiewowych przeciwciałInfo
- Publication number
- PL2542576T3 PL2542576T3 PL11751155.0T PL11751155T PL2542576T3 PL 2542576 T3 PL2542576 T3 PL 2542576T3 PL 11751155 T PL11751155 T PL 11751155T PL 2542576 T3 PL2542576 T3 PL 2542576T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- screening antibodies
- antibodies
- screening
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30972510P | 2010-03-02 | 2010-03-02 | |
US32343310P | 2010-04-13 | 2010-04-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2542576T3 true PL2542576T3 (pl) | 2016-10-31 |
Family
ID=44542524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL11751155.0T PL2542576T3 (pl) | 2010-03-02 | 2011-02-28 | Sposoby badań przesiewowych przeciwciał |
Country Status (11)
Country | Link |
---|---|
US (2) | US9725500B2 (pl) |
EP (1) | EP2542576B1 (pl) |
JP (5) | JP5797210B2 (pl) |
CN (1) | CN102858798B (pl) |
CA (1) | CA2788289C (pl) |
DK (1) | DK2542576T3 (pl) |
ES (1) | ES2581314T3 (pl) |
HK (1) | HK1180345A1 (pl) |
PL (1) | PL2542576T3 (pl) |
PT (1) | PT2542576T (pl) |
WO (1) | WO2011109308A1 (pl) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10107782B2 (en) | 2008-01-25 | 2018-10-23 | ProteinSimple | Method to perform limited two dimensional separation of proteins and other biologicals |
US9725500B2 (en) * | 2010-03-02 | 2017-08-08 | Seattle Genetics, Inc. | Methods for screening antibodies |
WO2013092998A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of antibodies |
EP2839276B1 (en) | 2012-04-19 | 2018-06-27 | ProteinSimple | Dual wavelength isoelectric focusing for determining drug load in antibody drug conjugates |
US10132799B2 (en) | 2012-07-13 | 2018-11-20 | Innate Pharma | Screening of conjugated antibodies |
WO2014072482A1 (en) | 2012-11-09 | 2014-05-15 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
EP2968582B1 (en) * | 2013-03-15 | 2020-07-01 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
GB2513405A (en) * | 2013-04-26 | 2014-10-29 | Adc Biotechnology Ltd | Method of synthesising ADCs using affinity resins |
EP3010547B1 (en) | 2013-06-20 | 2021-04-21 | Innate Pharma | Enzymatic conjugation of polypeptides |
KR20160042871A (ko) | 2013-06-21 | 2016-04-20 | 이나뜨 파르마, 에스.아. | 폴리펩티드의 효소적 콘쥬게이션 |
US9766206B2 (en) | 2013-09-27 | 2017-09-19 | ProteinSimple | Apparatus, systems, and methods for capillary electrophoresis |
KR102645430B1 (ko) | 2013-10-15 | 2024-03-11 | 씨젠 인크. | 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커 |
CN106536540A (zh) | 2014-07-24 | 2017-03-22 | 基因泰克公司 | 将试剂缀合至含有至少一个三硫键的蛋白质中的巯基部分的方法 |
GB201419185D0 (en) * | 2014-10-28 | 2014-12-10 | Adc Biotechnology Ltd | Method of synthesising ADCs using affinity resin |
KR20180021723A (ko) * | 2015-06-29 | 2018-03-05 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 선택적 제조 방법 |
KR102626498B1 (ko) | 2016-03-25 | 2024-01-19 | 씨젠 인크. | 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정 |
JP2020512312A (ja) | 2017-03-24 | 2020-04-23 | シアトル ジェネティックス, インコーポレイテッド | グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1203164A (en) * | 1982-03-09 | 1986-04-15 | Thomas J. Mckearn | Antibody conjugates |
WO2003000176A2 (en) | 2001-06-20 | 2003-01-03 | Molecular Staging, Inc. | Conjugates of reduced antibodies and biomolecules |
EE05402B1 (et) * | 2001-07-16 | 2011-04-15 | Janssen Pharmaceutica N.V. | Meetod bensimidasooli-tüüpi ühendite valmistamiseks ning k?rvalsaadusena moodustunud sulfoonide eemaldamiseks |
US20090068178A1 (en) * | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
US20030232386A1 (en) * | 2002-06-17 | 2003-12-18 | Shah Dinesh O. | Assay conjugate and uses thereof |
EP1545613B9 (en) * | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US20040038331A1 (en) | 2002-08-23 | 2004-02-26 | Reddy M. Parameswara | Solid phase synthesis of biomolecule conjugates |
SG195524A1 (en) | 2003-11-06 | 2013-12-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
AU2005218642B2 (en) | 2004-03-02 | 2011-04-28 | Seagen Inc. | Partially loaded antibodies and methods of their conjugation |
CN109045307A (zh) * | 2004-06-01 | 2018-12-21 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
KR20120064120A (ko) * | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
WO2007002222A2 (en) * | 2005-06-20 | 2007-01-04 | Psma Development Company, Llc | Psma antibody-drug conjugates |
WO2007100385A2 (en) * | 2005-10-31 | 2007-09-07 | Genentech, Inc. | Macrocyclic depsipeptide antibody-drug conjugates and methods |
MY150643A (en) * | 2006-06-22 | 2014-02-14 | Genentech Inc | Methods and compositions for targeting hepsin |
PL2502938T3 (pl) * | 2006-10-27 | 2015-07-31 | Genentech Inc | Przeciwciała i immunokoniugaty oraz ich zastosowanie |
US20080233660A1 (en) | 2007-03-23 | 2008-09-25 | Mu Bioteknik Ab | Solid phase labeling method |
PT2211904T (pt) | 2007-10-19 | 2016-11-02 | Seattle Genetics Inc | Agentes de ligação a cd19 e seus usos |
AR072804A1 (es) * | 2008-07-15 | 2010-09-22 | Genentech Inc | Conjugados derivados de antraciclina,proceso para su preparacion,composiciones farmaceuticas que los contienen y su uso como agentes antitumorales. |
CN102472747B (zh) | 2009-07-08 | 2015-04-29 | 伯乐实验室公司 | 单克隆抗体的纯化 |
US9725500B2 (en) * | 2010-03-02 | 2017-08-08 | Seattle Genetics, Inc. | Methods for screening antibodies |
-
2011
- 2011-02-28 US US13/581,236 patent/US9725500B2/en active Active
- 2011-02-28 PL PL11751155.0T patent/PL2542576T3/pl unknown
- 2011-02-28 JP JP2012556142A patent/JP5797210B2/ja active Active
- 2011-02-28 WO PCT/US2011/026534 patent/WO2011109308A1/en active Application Filing
- 2011-02-28 CA CA2788289A patent/CA2788289C/en active Active
- 2011-02-28 CN CN201180020718.1A patent/CN102858798B/zh active Active
- 2011-02-28 EP EP11751155.0A patent/EP2542576B1/en active Active
- 2011-02-28 ES ES11751155.0T patent/ES2581314T3/es active Active
- 2011-02-28 DK DK11751155.0T patent/DK2542576T3/en active
- 2011-02-28 PT PT117511550T patent/PT2542576T/pt unknown
-
2013
- 2013-06-25 HK HK13107386.2A patent/HK1180345A1/zh unknown
-
2015
- 2015-08-18 JP JP2015161040A patent/JP5998261B2/ja active Active
-
2016
- 2016-08-29 JP JP2016166921A patent/JP6291540B2/ja active Active
-
2017
- 2017-06-28 US US15/636,460 patent/US20170298118A1/en not_active Abandoned
-
2018
- 2018-02-09 JP JP2018021637A patent/JP6505882B2/ja active Active
-
2019
- 2019-03-27 JP JP2019060059A patent/JP6813928B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
DK2542576T3 (en) | 2016-08-01 |
US9725500B2 (en) | 2017-08-08 |
JP2015227891A (ja) | 2015-12-17 |
CA2788289A1 (en) | 2011-09-09 |
JP5998261B2 (ja) | 2016-09-28 |
WO2011109308A1 (en) | 2011-09-09 |
JP2018076386A (ja) | 2018-05-17 |
CA2788289C (en) | 2018-08-21 |
EP2542576A1 (en) | 2013-01-09 |
US20120322686A1 (en) | 2012-12-20 |
ES2581314T3 (es) | 2016-09-05 |
JP6813928B2 (ja) | 2021-01-13 |
EP2542576A4 (en) | 2013-09-04 |
CN102858798B (zh) | 2015-06-17 |
JP5797210B2 (ja) | 2015-10-21 |
EP2542576B1 (en) | 2016-04-20 |
JP2016216502A (ja) | 2016-12-22 |
CN102858798A (zh) | 2013-01-02 |
US20170298118A1 (en) | 2017-10-19 |
JP2013521498A (ja) | 2013-06-10 |
JP6505882B2 (ja) | 2019-04-24 |
JP6291540B2 (ja) | 2018-03-14 |
JP2019167339A (ja) | 2019-10-03 |
HK1180345A1 (zh) | 2013-10-18 |
PT2542576T (pt) | 2016-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1180345A1 (zh) | 篩選抗體的方法 | |
IL249501A0 (en) | A process for creating antibodies | |
HK1182625A1 (en) | Bispecific antibodies | |
ZA201209004B (en) | Anti-fgfr2 antibodies | |
GB201000467D0 (en) | Antibodies | |
IL221371A0 (en) | Anti-lrp6 antibodies | |
IL220404A (en) | Antiseptic antibodies | |
EP2685807A4 (en) | SCREENING METHODS | |
GB201103955D0 (en) | Antibodies | |
GB201112056D0 (en) | Antibodies | |
HK1194388A1 (zh) | 抗缺刻蛋白 抗體 | |
EP2686349A4 (en) | METHODS OF ANTIBODY SCREENING | |
PL2603528T3 (pl) | Przeciwciała Fab-glikozylowane | |
IL222533A0 (en) | Methods for detecting antibodies | |
GB201020738D0 (en) | Antibodies | |
EP2558587A4 (en) | METHOD FOR DISPLAYING ANTIBODIES | |
GB201002238D0 (en) | Antibodies | |
ZA201302459B (en) | Antibodies | |
GB201120317D0 (en) | Screening method | |
EP2758778A4 (en) | SCREENING PROCESS | |
EP2646824A4 (en) | SCREENING METHOD | |
EP2714074A4 (en) | ANTIBODIES AGAINST EMR1 | |
GB201015416D0 (en) | Screening method | |
GB201015419D0 (en) | Screening method | |
GB201006496D0 (en) | Screening method |